NCT01020279已完成1 期
Multiple-dose, Randomized, Subject and Observer Blinded, Placebo-controlled, Double-dummy Study of Epicutaneously Applied Ketoprofen Transfersome® Gel With or Without Combination With Oral Celecoxib for the Treatment of Muscle Pain Induced by Eccentric Exercise
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 82
- 试验地点
- 1
- 主要终点
- Pain during muscle contraction
研究概览
简要总结
- Comparison of the effect of ketoprofen Transfersome® gel (KTG) to placebo gel (PG) on muscle pain of the calf caused by eccentric contractions
- Comparison of the effect of KTG to celecoxib (CE) on muscle pain of the calf caused by eccentric contractions
- Comparison of the effect of celecoxib (CE) to oral placebo (OP) on muscle pain of the calf caused by eccentric contractions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Signed and dated informed consent prior to participation
- •Subjects in good health as determined by the Investigator
- •Age 18-55
- •Willing to abstain from any physical therapy, hard physical work, exercise or sauna during the study observation period (Screening to Final Visit)
- •For females, subjects of childbearing potential (including peri-menopausal women who have had a menstrual period within 1 year) must be using appropriate birth control (defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectables, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner). Oral contraceptive medications are allowed in this study. Female subjects, who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) are also allowed for participation
排除标准
- •Participation in another clinical study within the last 30 days and during the study
- •Subjects who are inmates of psychiatric wards, prisons, or other state institutions
- •Investigator or any other team member involved directly or indirectly in the conduct of the clinical study
- •Pregnancy or lactation
- •Alcohol or drug abuse
- •Malignancy within the past 2 years with the exception of in situ removal of basal cell carcinoma
- •Skin lesions, dermatological diseases or tattoo in the treatment areas
- •Known hypersensitivity or allergy (including photoallergy) to NSAID´s including celecoxib, sulfonamides and ingredients used in pharmaceutical products and cosmetics including galactose
- •Varicosis, thrombophlebitis and other vascular disorders of the lower extremities
- •Major traumatic lesions (e.g. fracture, tendon or muscle ruptures) of the musculo-skeletal system of the lower limbs
- •Pain conditions which might interfere with pain rating during the study, e.g. neuropathic pain
- •Significant neurological or psychiatric symptoms resulting in disorientation, memory impairment, or inability to report accurately (e.g. Alzheimer's disease or schizophrenia or other psychosis), that in the investigator's opinion may affect efficacy or safety assessments or may compromise subject safety during the study
- •Systemic lupus erythematodes, mixed connective tissue disease
- •Major heart disease / uncontrollable hypertension
- •Peripheral arterial disease and/or cerebrovascular disease
- •History of stroke or myocardial infarction
- •GFR < 30 ml/min
- •ALT and/or AST levels ≥ 5 times the ULN
- •Chronic obstructive pulmonary disease including asthma bronchiale
- •Coagulopathy or bleeding diathesis, or concomitant use of anticoagulants including low dose aspirin
- •History of pancreatitis or peptic ulcers
- •Inflammatory GI disease (e.g. M. Crohn, colitis ulcerosa)
- •Reflux esophagitis requiring treatment
- •Any other analgesic therapy including cough and cold drugs containing analgesic properties as well as any other substance used for the treatment of pain during the study observation period (Screening to final Visit)
- •Any other drug that might alter pain perception like CNS active drugs
研究组 & 干预措施
Parallel Group A
Other
Celecoxib 200 mg (Active Comparator) ; Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)
干预措施: Celecoxib, Ketoprofen (Drug)
Parallel Group B
Other
oral Placebo (Placebo Comparator); Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)
干预措施: Ketoprofen (Drug)
结局指标
主要结局
Pain during muscle contraction
时间窗: Day 7
次要结局
- Pain during rest(Day 7)
- Surface temperature(Day 7)
- Volume of the lower leg(Day 7)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
Ketoprofen Gel vs Placebo in Low Back PainMechanical Low Back PainNCT02491879Akdeniz University100
已完成
2 期
COMPARISON BETWEEN KETOPROFEN AND KETOPROFEN WITH DOXYCYCLINE GEL AS LOCAL DRUG DELIVERY IN SMOKERS AND NON SMOKERS CHRONIC PERIODONTITIS PATIENTS.CTRI/2020/03/024280MANUBHAI PATEL DENTAL COLLEGE AND ORALRESEARCH INSTITUTE21
Unknown
4 期
Comparison of Ketoprofen Gel to Placebo in Mechanical Low Back PainLow Back PainNCT02619695Akdeniz University160
已完成
不适用
Comparison of 2 patches for pain relief in patients undergoing gall bladder surgeryCTRI/2023/02/050001Ananta Institute of Medical Sciences80
终止
3 期
Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or BursitisTendonitisBursitisNCT00426985APR Applied Pharma Research s.a.381